uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade)
Source: SeekingAlpha
2026-03-03 08:15:20 ET
uniQure Overview
My last analysis of uniQure N.V. ( QURE ) followed a setback for its Huntington’s gene therapy, AMT-130. In an apparent reversal, the FDA reportedly no longer endorsed uniQure’s Phase 1/2 data—which featured a natural history external control. The company was hoping that the trial could serve as the backbone to a BLA. Then, uniQure intended to meet with the FDA....
Read the full article on Seeking Alpha
For further details see:
uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade)
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
